-
Pujiang Prostate Cancer Conference | Prof. Xiaojie Bian: Translating the Latest ASCO Advances into Precision Prostate Cancer Care and Driving Innovation in China
As one of China’s premier academic meetings in genitourinary oncology, the Pujiang Prostate Cancer Conference continues to serve as an important platform for integrating international advances with domestic clinical practice. This year’s meeting featured a dedicated multidisciplinary session, bringing together leading Chinese experts to discuss emerging directions in prostate cancer management.
-
Pujiang Prostate Cancer Conference | Prof. Guowen Lin: Three Key Assessment Dimensions for Selecting Candidates for Salvage Prostatectomy and New Surgical Strategies for Recurrence After Focal Ablation
The Pujiang Prostate Cancer Conference was held in Shanghai on June 26–27, 2026. Organized by the Shanghai Anti-Cancer Association and its Genitourinary Oncology Committee, and hosted by Fudan University Shanghai Cancer Center, the meeting focused on major clinical issues including salvage surgery following prostate cancer recurrence and the integration of multiple local treatment modalities.
-
Pujiang Prostate Cancer Conference | Prof. Yao Zhu: The Clinical Significance of the APCCC Consensus—Bridging Clinical Guidelines and Real-World Practice
The 2026 Pujiang Prostate Cancer Conference was held in Shanghai on June 26–27, 2026, under the theme “Standardization, Precision, Chinese Innovation, and Global Collaboration.” The conference featured in-depth discussions on key topics including early prostate cancer screening and precision diagnosis, optimization of local treatment strategies, innovation in advanced disease management, and the development of comprehensive…
-
Pujiang Prostate Cancer Conference | Prof. Bo Dai Shares Clinical Experience with the Hood Technique for Robot-Assisted Radical Prostatectomy
The 2026 Pujiang Prostate Cancer Conference was successfully held in Shanghai under the theme “Standardization, Precision, Chinese Innovation, and Global Collaboration,” with the goal of advancing standardized prostate cancer care and promoting innovation in key surgical techniques in China.
-
BOC Spotlight on Precision HER2 Therapy | Disitamab Vedotin Sets a New Benchmark for China’s Homegrown Innovation
In recent years, the treatment landscape for urothelial carcinoma (UC) has entered the era of precision medicine, with emerging therapeutic strategies offering new hope for patients. At the recent China Clinical Oncology Annual Advances Symposium (BOC) and Best of CSCO 2026 China, experts highlighted China’s most significant original oncology achievements of the year and reviewed…
-
Pujiang Prostate Cancer Conference | Prof. Xiaojian Qin Discusses the Clinical Value and Surgical Experience of Primary Tumor Resection in Metastatic Prostate Cancer
The 2026 Pujiang Prostate Cancer Conference was successfully held in Shanghai, bringing together leading experts to discuss the latest advances and clinical experience in prostate cancer management, further promoting standardized care and technological innovation in China.
-
Pujiang Prostate Cancer Conference | Prof. Yong Yang: The Predictive Value of Deep PSA Response and Treatment Optimization in mHSPC
The 2026 Pujiang Prostate Cancer Conference was held in Shanghai on June 26–27, 2026, under the theme “Standardization, Precision, Chinese Innovation, and Global Collaboration.” The meeting brought together leading experts in uro-oncology from across China to showcase advances in standardized prostate cancer management and cutting-edge research.
-
ASCO China Voice | Professors Claudio Vernieri & Man Li: PALMARES-2 Highlights the Potential of CDK4/6 Inhibitor Beyond Progression and Combined Local Therapy
At the 2026 ASCO Annual Meeting, Professor Claudio Vernieri from the Fondazione IRCCS Istituto Nazionale dei Tumori (Italy) presented the key findings of the PALMARES-2 study. Among patients with HR+/HER2− metastatic breast cancer, only about 20% continued first-line endocrine therapy (ET) plus a CDK4/6 inhibitor beyond first progression, achieving a median real-world progression-free survival (rwPFS)…
Connecting Medical Expertise through Media